Table 1.
Summary characteristics of studies with overlapping miRNAs in the same direction
| Obese | Sarcopenia | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MiRNA | Country | Obesity definition | N (%female) | Age (years) | Log2FC | Country | Sarcopenia definition | N (%female) | Age (years) | Log2FC | |
| Plasma | |||||||||||
| 1 | MiR‐106a‐5p | Spain 27 | BMI ≥ 30 kg/m2 |
Ob 12 (100%) Lean 19 (100%) |
Range 30–70 49.9 ± 11.3 45.1 ± 15.1 |
ND (Up) |
USA 31 |
Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
1.81 |
| 2 | MiR‐18b‐5p | New Zealand 28 | ND |
Ob 11 (100%) Lean 12 (100%) |
41 ± 5 44 ± 9 |
ND (Up) |
USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
4.00 |
| 3 | MiR‐193b‐5p | Singapore 29 | BMI ≥ 27.5 kg/m2 |
Ob 9 (0%) Lean 9 (0%) |
28.4 ± 1.6 a 23.2 ± 0.2 a |
1.89 | USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
1.96 |
| 4 | MiR‐197‐3p | New Zealand 28 | ND |
Ob 11 (100%) Lean 12 (100%) |
41 ± 5 44 ± 9 |
ND (Up) |
USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
1.85 |
| 5 | MiR‐199a‐5p | Singapore 29 | BMI ≥ 27.5 kg/m2 |
Ob 9 (0%) Lean 9 (0%) |
28.4 ± 1.6 a 23.2 ± 0.2 a |
−1.324 | USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
−0.74 |
| 6 | MiR‐483‐3p | Singapore 29 | BMI ≥ 27.5 kg/m2 |
Ob 9 (0%) Lean 9 (0%) |
28.4 ± 1.6 a 23.2 ± 0.2 a |
1.413 | USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
3.92 |
| 7 | MiR‐499 | New Zealand 28 | BMI > 30 kg/m2 |
Ob 80 (100%) Lean 80 (100%) |
52.5 ± 10.5 b 53.0 ± 13.5 b |
ND (Down) |
China 32 | AWGS |
S 93 (ND) N‐S 93 (ND) |
≥65 76.15 ± 0.58 a 76.19 ± 0.58 a |
Down |
| 8 | MiR‐550a‐3p | Singapore 29 | BMI ≥ 27.5 kg/m2 |
Ob 9 (0%) Lean 9 (0%) |
28.4 ± 1.6 a 23.2 ± 0.2 a |
0.782 | USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
3.08 |
| 9 | MiR‐576‐5p | Singapore 29 | BMI ≥ 27.5 kg/m2 |
Ob 9 (0%) Lean 9 (0%) |
28.4 ± 1.6 a 23.2 ± 0.2 a |
0.501 | USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
3.24 |
| 10 | MiR‐589‐5p | Singapore 29 | BMI ≥ 27.5 kg/m2 |
Ob 9 (0%) Lean 9 (0%) |
28.4 ± 1.6 a 23.2 ± 0.2 a |
0.274 | USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
1.81 |
| 11 | MiR‐92a‐3p | Singapore 29 | BMI ≥ 27.5 kg/m2 |
Ob 9 (0%) Lean 9 (0%) |
28.4 ± 1.6 a 23.2 ± 0.2 a |
0.571 | USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
0.78 |
| 12 | MiR‐1224‐5p | Singapore 29 | BMI ≥ 27.5 kg/m2 |
Ob 9 (0%) Lean 9 (0%) |
28.4 ± 1.6 a 23.2 ± 0.2 a |
0.987 | USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
0.49 |
| 13 | MiR‐1246 | Singapore 29 | BMI ≥ 27.5 kg/m2 |
Ob 9 (0%) Lean 9 (0%) |
28.4 ± 1.6 a 23.2 ± 0.2 a |
1.254 | USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
3.23 |
| 14 | MiR‐145‐5p | New Zealand 28 | ND |
Ob 11 (100%) Lean 12 (100%) |
41 ± 5 44 ± 9 |
Up | USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
3.23 |
| 15 | MiR‐196a‐5p | Singapore 29 | BMI ≥ 27.5 kg/m2 |
Ob 9 (0%) Lean 9 (0%) |
28.4 ± 1.6 a 23.2 ± 0.2 a |
0.885 | USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
1.48 |
| 16 | MiR‐296‐3p |
Singapore 29 |
BMI ≥ 27.5 kg/m2 |
Ob 9 (0%) Lean 9 (0%) |
28.4 ± 1.6 a 23.2 ± 0.2 a |
1.049 | USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
0.20 |
| 17 | MiR‐29b‐2‐5p | New Zealand 28 | ND |
Ob 11 (100%) Lean 12 (100%) |
41 ± 5 44 ± 9 |
ND (Up) |
USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
3.68 |
| 18 | MiR‐301b‐3p | Singapore 29 | BMI ≥ 27.5 kg/m2 |
Ob 9 (0%) Lean 9 (0%) |
28.4 ± 1.6 a 23.2 ± 0.2 a |
−0.973 | USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
−1.00 |
| 19 | MiR‐378c | Singapore 29 | BMI ≥ 27.5 kg/m2 |
Ob 9 (0%) Lean 9 (0%) |
28.4 ± 1.6 a 23.2 ± 0.2 a |
0.676 | USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
2.41 |
| 20 | MiR‐4732‐5p | Singapore 29 | BMI ≥ 27.5 kg/m2 |
Ob 9 (0%) Lean 9 (0%) |
28.4 ± 1.6 a 23.2 ± 0.2 a |
0.88 | USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
2.97 |
| 21 | MiR‐487a‐3p | Singapore 29 | BMI ≥ 27.5 kg/m2 |
Ob 9 (0%) Lean 9 (0%) |
28.4 ± 1.6 a 23.2 ± 0.2 a |
−1.3 | USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
−1.03 |
| 22 | MiR‐766‐3p | New Zealand 28 | ND |
Ob 11 (100%) Lean 12 (100%) |
41 ± 5 44 ± 9 |
ND (Up) |
USA 31 | Fried Frailty Phenotype |
Fr 7 (0%) N‐F 7 (71%) |
Range 71–89 85.6 ± 3.8 76 ± 6.5 |
1.14 |
| Serum | |||||||||||
| 23 | MiR‐23a‐3p | Korea 25 | BMI ≥ 35 kg/m2 |
Ob 16 (56%) Lean 18 (72%) |
Range 30–59 31.3 ± 8.76 38.6 ± 7.9 |
2.81 | USA 34 | EWGSOP 2010 |
S 12 (100%) N‐S 51 (100%) |
Range 60–85 ND ND |
1.66 (NS) |
| Vastus lateralis | |||||||||||
| 24 | MiR‐424‐5p | ND 35 | ND |
Ob 5 (0%) Lean 5 (0%) |
ND |
ND (Up) |
UK 33 | EWGSOP 2010 |
S 5 (0%) N‐S 59 (0%) |
Range 68–76 | Up |
AWGS, Asian Working Group for Sarcopenia; BMI, body mass index; EWGSOP, European Working Group on Sarcopenia in Older People; Fr, frail; IQR, inter‐quartile range; ND, not documented; N‐F, non‐frail; N‐S, non‐sarcopenic; NS, not statistically significant; Ob, obese; S, sarcopenic; SD, standard deviation; SEM, standard error of the mean.
Age is presented as mean ± SD unless specified.
±SEM.
Median ± IQR.